<- Go Home

Kenvue Inc.

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women’s health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee’s Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson’s, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson’s Baby, Johnson’s Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

Market Cap

$33.0B

Volume

31.2M

Cash and Equivalents

$1.1B

EBITDA

$3.5B

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$9.0B

Profit Margin

58.60%

52 Week High

$24.36

52 Week Low

$14.02

Dividend

4.83%

Price / Book Value

3.11

Price / Earnings

20.46

Price / Tangible Book Value

-4.52

Enterprise Value

$40.7B

Enterprise Value / EBITDA

11.57

Operating Income

$3.0B

Return on Equity

15.70%

Return on Assets

7.07

Cash and Short Term Investments

$1.1B

Debt

$8.8B

Equity

$10.6B

Revenue

$15.3B

Unlevered FCF

$2.1B

Sector

Personal Care Products

Category

N/A

Company Stock Pitches